Cipla has received approval to market Efavirenz tablets, from the US health regulator.

The company stated that, it has received final approval from the United States Food and Drug Administration (USFDA), for its abbreviated new drug application (ANDA) for Efavirenz tablets in 600mg strength and it is available for shipping immediately. It is used to treat HIV-1 infections in adults,

Further, Efavirenz tablets is the generic version of Bristol-Myers Squibb Pharma Company’s Sustiva, which is suggested in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults.

Read EquityPandit’s Technical Analysis of Cipla Outlook for the Week